Session » Systemic Lupus Erythematosus - Human Etiology and Pathogenesis Poster II

Date: Monday, November 9, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1870

A Lupus-Associated Variant in Purine Nucleoside Phosphorylase (PNP) Causes Cell Cycle Abnormalities

9:00AM-11:00AM: Abstract Number: 1861

Anti-Ds-DNA Antibodies Regulate Atherothrombosis in Systemic Lupus Erythematosus through the Induction of Netosis and the Prothrombotic and Proinflammatory Activities of Monocytes

9:00AM-11:00AM: Abstract Number: 1859

Anti-Interferon Autoantibodies in Systemic Lupus Erythematosus Are Biologically Active and Have Distinct Functions

9:00AM-11:00AM: Abstract Number: 1851

Antibody Against Ribonuclease-H Is a Novel Autoantibody Specifically Recognized in Systemic Lupus Erhythematosus

9:00AM-11:00AM: Abstract Number: 1865

Association Between Changes in Expression of Gene Signatures and Disease Activity Among Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1852

Association of Antibodies to the NR1 Subunit of N-Methyl-D-Aspartate Receptors with Neuropsychiatric Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1869

Association of CLEC16A with SLE in a Large Multi-Ancestry Cohort and Implication in B-Cell Receptor Signaling

9:00AM-11:00AM: Abstract Number: 1860

Autoantibodies Utilizing the Immunoglobulin Heavy Chain Variable Region Gene 4-34 (VH4-34) Exhibit Autoreactivity Towards, and Potential Competition with Galectins within Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 1853

Binding of a Novel IgG3 VH4-34 Monoclonal Antibody to ssRNA in SLE

9:00AM-11:00AM: Abstract Number: 1868

BLK Pathway-Associated rs13277113 GA Genotype Is More Frequent in Systemic Lupus Erythematosus Patients and Associated with Low Gene Expression and Increased Flares

9:00AM-11:00AM: Abstract Number: 1863

Epigenetic Changes in SLE Implicate Enhancers As a Force in Pathologic Cell Behavior

9:00AM-11:00AM: Abstract Number: 1856

Exosomes from Patients with Active Systemic Lupus Erythematosus Induce a Strong Inflammatory Response

9:00AM-11:00AM: Abstract Number: 1866

Fall in Dicer1 Gene Expression Flags Abnormal Lymphocyte Activation in Lupus

9:00AM-11:00AM: Abstract Number: 1871

Familial Aggregation of Rheumatoid Arthritis, Sjögren’s Syndrome, and Systemic Sclerosis Were Detected in Systemic Lupus Erythematous Families

9:00AM-11:00AM: Abstract Number: 1867

Functional Androgen Receptor Variants Associated with Greater Damage in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1864

H3K4me3 Peak Shape Dictates Transcription and Regulates Differential Expression in SLE

9:00AM-11:00AM: Abstract Number: 1845

HMGB1 Early Marker in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1854

Identification and Characterization of microRNAs Related to the Pathogenesis of Cardiovascular Disease in Patients with Antiphospholipid Syndrome and Systemic Lupus Erythematosus. Role of Specific Autoantibodies

9:00AM-11:00AM: Abstract Number: 1862

Identification of Homogeneous Systemic Lupus Erythematosus (SLE) Patient Groups Using Clustered Autoantibody Reactivities

9:00AM-11:00AM: Abstract Number: 1857

Identification of the Long Noncoding RNA NEAT1 As a Novel Inflammatory Regulator Acting through MAPK Pathway in Human Lupus

9:00AM-11:00AM: Abstract Number: 1846

IGFBP-2 As a Novel Biomarker for Disease Activity and Renal Pathology in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1848

Increased Expression of Bruton Tyrosine Kinase in Patients with Lupus Nephritis and Its Clinic Significance

9:00AM-11:00AM: Abstract Number: 1850

Increased Levels of Immunoglobulin Binding Protein 1 Are Associated with Disease Activity Including Renal Damage in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1849

Serum Axl and Tumor Necrosis Factor Receptor II Portend Long-Term Renal Outcome in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1847

Serum Ferritin and Insulin-like Growth Factor-Binding Protein 2 As Biomarkers of Clinical and Histopathological Treatment Response in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1858

Serum Tartrate Resistant Acid Phosphatase (TRAP) Levels Are Decreased and Associated with Anti-Maa Antibodies in Systemic Lupus Erythematosus (SLE) Patients

9:00AM-11:00AM: Abstract Number: 1855

Systemic Lupus Erythematosus Exosomes Contain Distinct RNA Transcripts That Differentiate Disease Activity and Modulate Cellular Function

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].